FDA grants J&J accelerated approval for head and neck cancer treatment
JNJ•The FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for certain patients with advanced head and neck cancer. In a trial of 102 patients, tumors shrank or disappeared in 42% of those treated.
1. Approval and trial results
The FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease worsened after chemotherapy and immunotherapy. The decision was based on a trial of 102 patients, in which 42% saw their tumors shrink or disappear. The FDA said effective treatment options for this hard-to-treat cancer remain limited.
